Kiniksa Pharmaceuticals International (KNSA) revenue

Revenue · fiscal 2025
$677.56M

Kiniksa Pharmaceuticals International (KNSA) reported revenue of $677.56M in fiscal 2025 (the year ended December 31, 2025). That is 60.1% higher than the $423.24M of fiscal 2024. Figures as of 18 Nov 2026, 09:27 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$677.56M
Change on fiscal 2024
+60.1%
Highest on record
$677.56Mfiscal 2025
Lowest on record
$38.54Mfiscal 2021
Fiscal years on record
52021–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Kiniksa Pharmaceuticals International revenue, in more detail

Across the 5 fiscal years on record (2021–2025), the highest was $677.56M in fiscal 2025 and the lowest $38.54M in fiscal 2021.

History · 5 fiscal years

Revenue by fiscal year

Kiniksa Pharmaceuticals International revenue, year by year

Kiniksa Pharmaceuticals International (KNSA) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$677.56M 60.1% up
2024$423.24M 56.6% up
2023$270.26M 22.7% up
2022$220.18M 471.2% up
2021$38.54M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Kiniksa Pharmaceuticals International and comparable companies
CompanyRevenueFiscal year
Alkermes ALKS$1.48B2025
PACS Group PACS$5.29B2025
Kiniksa Pharmaceuticals International KNSA$677.56M2025
ImmunityBio IBRX$113.29M2025
Cytokinetics CYTK$88.04M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on KNSA

Kiniksa Pharmaceuticals International, figure by figure

Kiniksa Pharmaceuticals International (KNSA) overview: price, valuation and scorecardAll health care companies by market value

Kiniksa Pharmaceuticals International revenue: questions and answers

What is Kiniksa Pharmaceuticals International's revenue?

Kiniksa Pharmaceuticals International (KNSA) reported revenue of $677.56M in fiscal 2025 (the year ended December 31, 2025). That is 60.1% higher than the $423.24M of fiscal 2024.

What are the highest and lowest revenue figures on record for Kiniksa Pharmaceuticals International?

Across the 5 fiscal years on record (2021–2025), the highest was $677.56M in fiscal 2025 and the lowest $38.54M in fiscal 2021.

How is Kiniksa Pharmaceuticals International's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Kiniksa Pharmaceuticals International it is on record here for 5 fiscal years, 2021 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Kiniksa Pharmaceuticals International (KNSA) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/KNSA/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.